Losartan-ratiopharm may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan-ratiopharm in the following countries:
International Drug Name Search
Daktarin Oral may be available in the countries listed below.
Miconazole is reported as an ingredient of Daktarin Oral in the following countries:
International Drug Name Search
Nastil may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Nastil in the following countries:
International Drug Name Search
Niux may be available in the countries listed below.
Pefloxacin mesilate (a derivative of Pefloxacin) is reported as an ingredient of Niux in the following countries:
International Drug Name Search
Vitamine B12 Théa may be available in the countries listed below.
Cyanocobalamin is reported as an ingredient of Vitamine B12 Théa in the following countries:
International Drug Name Search
In the US, Novolog Mix 70/30 (insulin aspart/insulin aspart protamine systemic) is a member of the drug class insulin and is used to treat Diabetes - Type 1 and Diabetes - Type 2.
US matches:
Insulin Aspart is reported as an ingredient of Novolog Mix 70/30 in the following countries:
International Drug Name Search
Novofemme may be available in the countries listed below.
Estradiol hemihydrate (a derivative of Estradiol) is reported as an ingredient of Novofemme in the following countries:
Norethisterone 17ß-acetate (a derivative of Norethisterone) is reported as an ingredient of Novofemme in the following countries:
International Drug Name Search
Treating infections caused by certain bacteria. It may be used in combination with other medicines to treat certain amoeba infections. It may also be used to prevent or slow the progression of anthrax after exposure.
Doxy 100 is a tetracycline antibiotic. It works by slowing the growth of bacteria. Slowing bacteria's growth allows the body's immune system to destroy the bacteria.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Doxy 100. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Doxy 100. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Doxy 100 may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Doxy 100 as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Doxy 100.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Loss of appetite; nausea; sensitivity to sunlight; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); bloody stools; chest pain; dark urine; decreased urination; fever, chills, or sore throat; moderate to severe sunburn; red, swollen, blistered, or peeling skin; severe diarrhea; severe or persistent headache; stomach pain or cramps; throat irritation; trouble swallowing; unusual bruising or bleeding; unusual joint pain; unusual tiredness; vaginal irritation or discharge; vision changes; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Doxy00 side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store mixed powder at 77 degrees F (25 degrees C) for up to 48 hours. Mixed solution is stable under fluorescent light for 48 hours, but must be protected from direct sunlight during storage and administration. Mixed solution may be stored up to 72 hours before administration if refrigerated and protected from sunlight and artificial light. Infusion must be completed within 12 hours of mixing. Throw away any unused portion. Keep Doxy 100 out of the reach of children and away from pets.
When frozen immediately after mixing in sterile water, the solution is stable for up to 8 weeks when stored at 68 degrees F (20 degrees C). If the product is warmed, avoid heating it after the thawing is complete. Do not refreeze the solution once it has been thawed.
This information is a summary only. It does not contain all information about Doxy 100. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Novolin Flexpen 50R may be available in the countries listed below.
Insulin Injection, Biphasic Isophane human (a derivative of Insulin Injection, Biphasic Isophane) is reported as an ingredient of Novolin Flexpen 50R in the following countries:
International Drug Name Search
Sodium Ozagrel may be available in the countries listed below.
Ozagrel sodium (a derivative of Ozagrel) is reported as an ingredient of Sodium Ozagrel in the following countries:
International Drug Name Search
Novotossil may be available in the countries listed below.
Cloperastine hydrochloride (a derivative of Cloperastine) is reported as an ingredient of Novotossil in the following countries:
International Drug Name Search
Claritromicina Tarbis may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Claritromicina Tarbis in the following countries:
International Drug Name Search
Merbentyl Syrup
Dicycloverine Hydrochloride 10mg
Syrup
Merbentyl is a smooth muscle antispasmodic primarily indicated for treatment of functional conditions involving smooth muscle spasm of the gastrointestinal tract. The commonest of these are irritable colon (mucous colitis, spastic colon).
Adults
One to two 5ml spoonfuls (10 - 20mg) three times daily before or after meals.
Children (2-12 years):
One 5ml spoonful (10mg) three times daily.
Children (6 months - 2 years)
5 - 10mg three or four times daily, 15 minutes before feeds. Do not exceed a daily dose of 40mg. If it is necessary to dilute Merbentyl Syrup this may be done using Syrup or if diluted immediately prior to use with water.
Known idiosyncrasy to dicycloverine hydrochloride. Infants under 6 months of age.
Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Products containing dicycloverine hydrochloride should be used with caution in any patient with or suspected of having glaucoma or prostatic hypertrophy. Use with care in patients with hiatus hernia associated with reflux oesophagitis because anticholinergic drugs may aggravate the condition. There are reports of infants, 3 months of age and under, administered dicycloverine hydrochloride syrup who have evidenced respiratory symptoms (breathing difficulty, shortness of breath, breathlessness, respiratory collapse, apnoea) as well as seizures, syncope, asphyxia, pulse rate fluctuations, muscular hypotonia and coma. The above symptoms have occurred within minutes of ingestion and lasted 20-30 minutes. The symptoms were reported in association with dicycloverine hydrochloride syrup therapy but the cause and effect relationship has neither been disproved or proved. The timing and nature of the reactions suggest that they were a consequence of local irritation and/or aspiration, rather than to a direct pharmacological effect. Although no causal relationship between these effects, observed in infants and dicycloverine administration has been established, dicycloverine hydrochloride is contra-indicated in infants under 6 months of age.
None stated.
Epidemiological studies in pregnant women with products containing dicycloverine hydrochloride (at doses up to 40mg/day) have not shown that dicycloverine hydrochloride increases the risk of foetal abnormalities if administered during the first trimester of pregnancy. Reproduction studies have been performed in rats and rabbits at doses of up to 100 times the maximum recommended dose (based on 60mg per day for an adult person) and have revealed no evidence of impaired fertility or harm to the foetus due to dicycloverine. Since the risk of teratogenicity cannot be excluded with absolute certainty for any product, the drug should be used during pregnancy only if clearly needed.
It is not known whether dicycloverine is secreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dicycloverine is administered to a nursing mother.
None stated.
Side-effects seldom occur with Merbentyl. However, in susceptible individuals, dry mouth, thirst and dizziness may occur. On rare occasions, fatigue, sedation, blurred vision, rash, constipation, anorexia, nausea and vomiting, headache and dysuria have also been reported.
Symptoms of Merbentyl overdosage are headache, dizziness, nausea, dry mouth, difficulty in swallowing, dilated pupils and hot dry skin. Treatment may include emetics, gastric lavage and symptomatic therapy if indicated.
Dicycloverine hydrochloride relieves smooth muscle spasm of the gastrointestinal tract.
Animal studies indicate that this action is achieved via a dual mechanism;
(1) a specific anticholinergic effect (antimuscarinic at the ACh-receptor sites) and
(2) a direct effect upon smooth muscle (musculotropic).
After a single oral 20mg dose of dicycloverine hydrochloride in volunteers, peak plasma concentration reached a mean value of 58ng/ml in 1 to 1.5 hours. 14C labelled studies demonstrated comparable bioavailability from oral and intravenous administration. The principal route of elimination is via the urine.
None stated.
Invert Syrup Medium
Citric Acid Monohydrate
Sodium Benzoate
Raspberry Flavour
Wild Cherry Bark Flavour
Blackcurrant Essence
Vanilla Essence
Purified water
None stated.
3 years.
Do not store above 25'C. Should be stored and dispensed in amber glass bottles.
Type III, EP amber glass bottles sealed with a polyethylene screw cap equiped with a polyethylene seal and pilferproof closure.
Pack size: 1 bottle containing 120ml syrup.
None stated.
Sanofi-aventis
One Onslow Street
Guildford
Surrey, GU1 4YS, UK
PL 04425/0047
Date of first authorisation: 13th July 1983
Date of renewal: 31 July 2001
December 2006
Legal category: POM
Atenolol Gador may be available in the countries listed below.
Atenolol is reported as an ingredient of Atenolol Gador in the following countries:
International Drug Name Search
Novolizer Budesonide may be available in the countries listed below.
Budesonide is reported as an ingredient of Novolizer Budesonide in the following countries:
International Drug Name Search
Bactroban 2% Ointment
mupirocin
Bactroban 2% Ointment (called ‘Bactroban’ in this leaflet) contains a medicine called mupirocin.
Bactroban is an antibiotic ointment.
It is used:
Do not use if the above applies to you. If you are not sure do not use this medicine. Talk to your doctor, nurse or pharmacist before using Bactroban.
Thrush (a yeast infection) may develop if Bactroban is used for a long time. If this occurs, tell your doctor, pharmacist or nurse.
Keep the ointment away from your eyes.
There is a different preparation of Bactroban that is used to prevent or treat infections inside your nose.
Please tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, including herbal medicines.
Do not use Bactroban if you are pregnant, might become pregnant or are breast-feeding. Talk to your doctor, nurse or pharmacist for advice before using any medicine, if you are pregnant or breast-feeding. If a cracked nipple is being treated, the ointment must be thoroughly washed off prior to breast-feeding.
Always use Bactroban exactly as your doctor has told you. You should check with your doctor, nurse or pharmacist if you are not sure.
Do not mix Bactroban with any other external cream or ointment medicines on the infected area of your skin as this may reduce the effectiveness of Bactroban.
You usually apply Bactroban on your skin up to 3 times a day.
Use Bactroban for as long as your doctor has told you. If you are not sure, ask your doctor, nurse or pharmacist. The bacteria are normally cleared from your skin within 10 days of starting treatment.
Do not use for more than 10 days.
If you use more Bactroban than you should, speak to your doctor, nurse or pharmacist for advice.
If you stop using Bactroban too early, not all the bacteria may have been killed or they may continue to grow. Ask your doctor, nurse or pharmacist when to stop using the ointment.
If you have any further questions on the use of this product, ask your doctor, nurse or pharmacist.
Like all medicines, Bactroban can cause side effects, although not everybody gets them.
Severe skin reactions or allergies
The following side effects may happen with this medicine:
Common (these may affect between 1 in 10 and 1 in 100 people)
Uncommon (these may affect between 1 in 100 and 1 in 1,000 people)
Very rare (these may affect up to 1 in 10,000 people)
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.
Marketing authorisation holder
Manufacturer
Other formats:
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000 (UK Only)
Please be ready to give the following information:
Product Name: Bactroban 2% Ointment
Reference number: 00038/0319
This is a service provided by the Royal National Institute for the Blind.
Leaflet date: January 2010
Bactroban is a registered trademark of the GlaxoSmithKline group of companies.
© 2010 GlaxoSmithKline group of companies.
10000000078208
Novo-Spirozine may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Novo-Spirozine in the following countries:
Spironolactone is reported as an ingredient of Novo-Spirozine in the following countries:
International Drug Name Search
Novolin ge 50/50 may be available in the countries listed below.
Insulin, Isophane human (a derivative of Insulin, Isophane) is reported as an ingredient of Novolin ge 50/50 in the following countries:
International Drug Name Search
Novogyn may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Novogyn in the following countries:
Levonorgestrel is reported as an ingredient of Novogyn in the following countries:
International Drug Name Search
Flumirex may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Flumirex in the following countries:
International Drug Name Search
